179 related articles for article (PubMed ID: 35522566)
1. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.
Giesche J; Mellert K; Geißler S; Arndt S; Seeling C; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TF
J Pathol; 2022 Aug; 257(5):687-696. PubMed ID: 35522566
[TBL] [Abstract][Full Text] [Related]
2. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
3. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
4. Drivers underpinning the malignant transformation of giant cell tumour of bone.
Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
[TBL] [Abstract][Full Text] [Related]
5. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.
Guimarães LM; Baumhoer D; Andrei V; Friedel D; Koelsche C; Gomez RS; von Deimling A; Gomes CC
J Pathol Clin Res; 2023 Nov; 9(6):464-474. PubMed ID: 37555357
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
[TBL] [Abstract][Full Text] [Related]
8. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
[TBL] [Abstract][Full Text] [Related]
9. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
[TBL] [Abstract][Full Text] [Related]
10. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
11. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
12. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
13. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
14. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
[TBL] [Abstract][Full Text] [Related]
15. [Giant cell tumor of bone-an update].
Tschavoll F; Lutteri G; Leinauer B; Mellert K; Möller P; Barth TFE
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):215-219. PubMed ID: 37985483
[TBL] [Abstract][Full Text] [Related]
16. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.
Lübbehüsen C; Lüke J; Seeling C; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Möller P; Barth TFE
Sci Rep; 2019 Apr; 9(1):6458. PubMed ID: 31015476
[TBL] [Abstract][Full Text] [Related]
19. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
Han YX; Liang DY
Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
[TBL] [Abstract][Full Text] [Related]
20. Gene of the month: H3F3A and H3F3B.
Aldera AP; Govender D
J Clin Pathol; 2022 Jan; 75(1):1-4. PubMed ID: 34782425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
